(MENAFN- PR Newswire)
NEW YORK, Aug. 4, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of ChemoCentryx, Inc. ('ChemoCentryx' or the 'Company') (NASDAQ: CCXI ), in connection with the proposed acquisition of the Company by Amgen Inc. (NASDAQ: AMGN ).Under the terms of the merger agreement, the Company's shareholders will receive $52.00 in cash for each share of ChemoCentryx common stock owned. The transaction is valued at approximately $3.7 billion.
If you own ChemoCentryx shares and wish to discuss this investigation or have any questions concerning this notice or your rights or interests, visit our website:
Or please contact: Joshua Rubin, Esq. Weiss Law 305 Broadway, 7th FloorNew York, NY 10007 (212) 682-3025 (888) 593-4771[email protected]
Weiss Law is investigating whether (i) ChemoCentryx's board of directors acted in the best interests of Company shareholders in agreeing to the proposed transaction, (ii) the $52.00 per-share merger consideration adequately compensates ChemoCentryx's shareholders, and (iii) all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed. Notably, the merger consideration is below the $64.50 median price target set by analysts, and at least one analyst set a price target for the Company of $106 per share, $54.00 above the per-share merger consideration.
Weiss Law has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties. We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases. If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at [email protected]
SOURCE Weiss Law
Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.